0000899243-23-002395.txt : 20230123
0000899243-23-002395.hdr.sgml : 20230123
20230123163321
ACCESSION NUMBER: 0000899243-23-002395
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230119
FILED AS OF DATE: 20230123
DATE AS OF CHANGE: 20230123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Howze Yalonda
CENTRAL INDEX KEY: 0001828153
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39615
FILM NUMBER: 23544854
MAIL ADDRESS:
STREET 1: C/O CODIAK BIOSCIENCES, INC.
STREET 2: 35 CAMBRIDGEPARK DRIVE, SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Codiak BioSciences, Inc.
CENTRAL INDEX KEY: 0001659352
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 CAMBRIDGEPARK DRIVE
STREET 2: SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
BUSINESS PHONE: 617-949-4100
MAIL ADDRESS:
STREET 1: 35 CAMBRIDGEPARK DRIVE
STREET 2: SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
FORMER COMPANY:
FORMER CONFORMED NAME: Codiak Biosciences, Inc.
DATE OF NAME CHANGE: 20151125
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-19
0
0001659352
Codiak BioSciences, Inc.
CDAK
0001828153
Howze Yalonda
C/O CODIAK BIOSCIENCES, INC.
35 CAMBRIDGEPARK DRIVE, SUITE 500
CAMBRIDGE
MA
02140
0
1
0
0
See Remarks
Common Stock
2023-01-19
4
M
0
4000
A
4000
D
Common Stock
2023-01-20
4
S
0
1512
0.5752
D
2488
D
Restricted Stock Units
2023-01-19
4
M
0
4000
0.00
D
Common Stock
4000
8000
D
Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement.
Each RSU represents a contingent right to receive one share of common stock.
On January 19, 2022, the reporting person was granted 12,000 RSUs, vesting in three equal annual installments beginning on the first anniversary of the grant date.
Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary
/s/ Yalonda Howze
2023-01-23